Accès gratuit
Med Sci (Paris)
Volume 21, Numéro 12, Décembre 2005
Page(s) 1045 - 1053
Section M/S revues
Publié en ligne 15 décembre 2005
  1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37 : 1595–607.
  2. Palinski W, Napoli C. The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterol-lowering or antioxydant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis. FASEB J 2002; 16 : 1348–60.
  3. Alberti KGMM, Zimmet PZ. For the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I. Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998; 15 : 539–53.
  4. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report on the National cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 2001; 285 : 2486–97.
  5. The European group for the study of insulin resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002; 28 : 364–76.
  6. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350 : 2362–74.
  7. Tounian P, Aggoun Y, Dubern B, et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet 2001; 358 : 1400–4.
  8. New guidelines for metabolic syndrome. Pharma Marketletter 2005; April 25 : 21.
  9. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland coronary prevention study. Circulation 2003; 108 : 414–9.
  10. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worlwide populations. Endocrinol Metab Clin North Am 2004; 33 : 351–75.
  11. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365 : 1415–28.
  12. Balkau B, Vernay M, Mhamdi L, et al. The incidence and persistence of the NCEP (National cholesterol education program) metabolic syndrome. The French DESIR study. Diabetes Metab 2003; 29 : 526–32.
  13. Gamila S, Dallongeville J. Épidémiologie du syndrome métabolique en France. Med Nutr 2003; 39 : 89–94.
  14. Standl E. Aetiology and consequences of the metabolic syndrome. Eur Heart J 2005; 7 (suppl) : D10–13.
  15. Lau DCW, Dhillon B, Yan H, et al. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol 2005; 288 : H2031–41.
  16. Pritchett AM, Foreyt JP, Mann DL. Treatment of the metabolic syndrome: the impact of lifestyle modification. Curr Atheros Rep 2005; 7 : 95–102.
  17. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM trial. JAMA 2003; 290 : 486–94.
  18. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334 : 574–9.
  19. Yki-Järvinen. Thiazolidinediones. N Engl J Med 2004; 351 : 1106–18.
  20. Li AC, Binder CJ, Gutierrez A, et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and g. J Clin Invest 2004; 114 : 1564–76.
  21. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus. Results from a controlled randomized study. Circulation 2005; 111 : 2525–31.
  22. Khan MA, St Peter JV, Xue JL. A prospective, randomised comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002; 25 : 708–11.
  23. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease : the Scandinavian simvastatin survival study (4S). Lancet 1994; 344 : 1383–9.
  24. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidemia and future perspectives. Atherosclerosis 2003; 171 : 1–13.
  25. Bloomfield Rubins H, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341 : 410–8.
  26. Heart protection study collaborative group. MRC/BHF Heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361 : 2560–72.
  27. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 report. JAMA 2003; 289 : 2560–72.
  28. Effets of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the Hope study and Micro-Hope substudy. Lancet 2000; 355 : 253–9.
  29. Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan intervention for endpoint reduction in hypertension study (Life): a randomised trial against atenolol. Lancet 2002; 359 : 1004–10.
  30. Yvan-Charvet L, Even P, Bloch-Faure M, et al. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 2005; 54 : 991–9.
  31. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of Telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 2004; 43 : 993–1002.
  32. Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005; 26 : 244–50.
  33. Wang YX, Lee CH, Tiep S, et al. Peroxisome-proliferator activated receptor d activates fat metabolism to prevent obesity. Cell 2003; 113 : 159–70.
  34. Metabolex PPAR modulator shows no weight gain or oedema. SCRIP 2005; 3043 : 23.
  35. Howlett AC, Breivogel CS, Childers SR, et al. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004; 47 : 345–58.
  36. Steffens S, Veillard NR, Arnaud C, et al. Low dose of oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005; 434 : 782–6.
  37. Fernandez JR, Allison DB. Rimonabant Sanofi-Synthelabo. Curr Opin Investig Drugs 2004; 4 : 430–5.
  38. Boyd ST, Fremming BA. Rimonabant: a selective CB1 antagonist. Ann Pharmacother 2005; 39 : 684–90.
  39. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev 2005; 4 : 193–205.
  40. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. JAMA 2003; 290 : 2292–300.
  41. Birjmohon RS, Hutten BA, Kastelein JJP, Stroes ESG. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005; 45 : 185–97.
  42. Meyers CD, Kashyap ML. Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies. Curr Opin Cardiol 2005; 20 : 307–12.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.